1Libby P. Inflammation in atherosclerosis [ J ]. Nature, 2002,420 : 868 - 874.
2Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor ceils, vascular function, and cardiovascular risk [J]. N Engl J Med, 2003, 348:593-600.
3Goldschmidt-Clermont PJ, Creager MA, Losordo DW, et al. Atherosclerosis 2005: recent discoveries and novel hypotheses[J]. Circulation, 2005, 112(21) :3348 -3353.
4Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque[ J ]. J Am Coil Cardiol, 2006, 47 (8 Suppl) :C13 -8.
5Insull WJ. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment[J]. Am J Med, 2009, 122(1 Suppl) :S3-S14.
6Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events ( Naples ) II trial: impact of a single high loading dose of atorvastatin on peri- procedural myocardial infarction [ J ]. J Am Coll Cardiol, 2009, 54(23) :2157 - 2163.
7Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early pereutaneous coronary intervention: results of the ARMYDA-ACS randomized trial[J].J Am Coll Cardiol, 2007, 49(12) :1272-1278.
8Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention : results of the ARMYDA- RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty ) Randomized Trial [J]. J Am Coll Cardiol, 2009, 54(6) :558-565.
9Roiren D, Sanchez P, Bouzamondo A, et al. Drag eluting stents: an updated Meta-analysis of randomized controlled trials[J]. Heart, 2006, 92:641-649.
10Tonino PL, De Bruyne B, Pijls NJ, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med, 2009,360:213-224.
4Rayn TJ,Faxon DP,Gunnar RM,et al.Guidelines for percutaneous transluminal coronary angioplasty:A report of the American College of Cardiology American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).J Am Coll Cardiol 1988; 12:529.
5Ellis SG,Vandormael MG,Cowley M J,et al.Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease.Implications for patient selection.Circulation 1999 ;82:1193.
6Degertekin M,Serruys PW,Foley DP,et al.Persistant inhi bition of neointimal hyperplasia after sirolimus-eluting stent implantation:long term (up to 2 years) clinical,angiographic,and intravascular ultrasound follow-up.Circulation 2002; 106:1610-1613.
7Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med 2002; 346:1773-1780.
8Waksman R.Drug-eluting stents:from bench to bed.Cardiovasc Radiat Med 2002; 3 (3-4):226-241.
9Froeschl M,Olsen S,Ma X,et al.Current understanding of in-stent restenosis and the potential benefit of drug eluting stents.Curt Drug Targets Cardiovasc Haematol Disord 2004;4(1):103-117.
